BNP Paribas Financial Markets Has $5.96 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

BNP Paribas Financial Markets increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 269.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 395,695 shares of the company's stock after purchasing an additional 288,662 shares during the period. BNP Paribas Financial Markets owned approximately 0.86% of Pacira BioSciences worth $5,955,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Jane Street Group LLC grew its position in Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company's stock valued at $5,480,000 after acquiring an additional 177,557 shares during the last quarter. GAMMA Investing LLC grew its position in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after acquiring an additional 932 shares during the last quarter. QRG Capital Management Inc. grew its position in Pacira BioSciences by 37.9% in the second quarter. QRG Capital Management Inc. now owns 31,309 shares of the company's stock valued at $896,000 after acquiring an additional 8,601 shares during the last quarter. SG Americas Securities LLC grew its position in Pacira BioSciences by 255.6% in the second quarter. SG Americas Securities LLC now owns 12,858 shares of the company's stock valued at $368,000 after acquiring an additional 9,242 shares during the last quarter. Finally, Gradient Investments LLC grew its position in Pacira BioSciences by 14.6% in the second quarter. Gradient Investments LLC now owns 158,610 shares of the company's stock valued at $4,538,000 after acquiring an additional 20,183 shares during the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Trading Up 13.6 %

PCRX stock traded up $2.27 during trading on Wednesday, hitting $18.95. The company had a trading volume of 673,227 shares, compared to its average volume of 843,453. The business has a 50-day moving average of $16.58 and a 200-day moving average of $19.57. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The stock has a market cap of $874.92 million, a PE ratio of -8.86 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Analyst Ratings Changes

A number of research firms have issued reports on PCRX. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Pacira BioSciences in a research report on Friday, November 8th. Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 12th. Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Jefferies Financial Group boosted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. Finally, HC Wainwright restated a "buy" rating and set a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.